TNFRSF17 and plasma cell myeloma: ABECMA (idecabtagene vicleucel) is approved for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy including an immunomodulatory agent and it targets B-cell maturation antigen (BCMA).